BioScrip, Inc. (NASDAQ:BIOS) – Equities researchers at Barrington Research upped their Q4 2017 earnings estimates for BioScrip in a report issued on Monday. Barrington Research analyst M. Petusky now forecasts that the company will post earnings per share of ($0.01) for the quarter, up from their prior forecast of ($0.02). Barrington Research currently has a “Outperform” rating and a $3.50 price target on the stock. Barrington Research also issued estimates for BioScrip’s Q3 2018 earnings at ($0.07) EPS, Q4 2018 earnings at $0.02 EPS, FY2018 earnings at ($0.23) EPS and FY2019 earnings at ($0.05) EPS.
BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Thursday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.04. The firm had revenue of $217.80 million for the quarter, compared to the consensus estimate of $230.23 million. The firm’s quarterly revenue was down 8.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.17) EPS.
ILLEGAL ACTIVITY WARNING: “Equities Analysts Set Expectations for BioScrip, Inc.’s Q4 2017 Earnings (BIOS)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/07/25/equities-analysts-set-expectations-for-bioscrip-inc-s-q4-2017-earnings-bios-updated-updated.html.
Other analysts also recently issued research reports about the company. Jefferies Group LLC upped their target price on BioScrip from $2.50 to $3.00 and gave the stock a “buy” rating in a research note on Monday, March 6th. Zacks Investment Research upgraded BioScrip from a “sell” rating to a “hold” rating in a research note on Wednesday.
Shares of BioScrip (BIOS) opened at 2.61 on Wednesday. The company’s market cap is $315.76 million. BioScrip has a 1-year low of $0.98 and a 1-year high of $3.43. The stock has a 50 day moving average of $2.17 and a 200 day moving average of $1.70.
Hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. increased its position in shares of BioScrip by 65.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,257 shares of the company’s stock worth $109,000 after buying an additional 25,500 shares in the last quarter. American International Group Inc. increased its position in shares of BioScrip by 73.8% in the first quarter. American International Group Inc. now owns 67,812 shares of the company’s stock worth $115,000 after buying an additional 28,787 shares in the last quarter. Alambic Investment Management L.P. acquired a new position in shares of BioScrip during the first quarter worth about $160,000. Citadel Advisors LLC acquired a new position in shares of BioScrip during the first quarter worth about $161,000. Finally, Teachers Advisors LLC increased its position in shares of BioScrip by 14.0% in the fourth quarter. Teachers Advisors LLC now owns 162,778 shares of the company’s stock worth $169,000 after buying an additional 20,000 shares in the last quarter. Hedge funds and other institutional investors own 83.06% of the company’s stock.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Stock Ratings for BioScrip Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioScrip Inc. and related stocks with our FREE daily email newsletter.